Back to all Portfolio news
November 20, 2006

Albert A. Luderer, Former bioMerieux Exec, Joins Micronics’ Board of Directors

Redmond, WA – November 20, 2006 – Micronics, Inc., developer of near patient point of care diagnostic products, announced today that Albert A. Luderer, Ph.D., has been named to its Board of Directors, effective immediately. Dr. Luderer currently serves as CEO of BioTrove, Inc. and has more than 20 years experience in medical diagnostics management and technology development.

“Al’s extensive, global expertise in product development for medical diagnostics and healthcare companies lends itself to Micronics’ growth strategy,” said Karen Hedine, Micronics’ president and chief executive officer. “Al’s particular strengths in having managed both established diagnostics companies, like bioMerieux Inc., as well as in building value in development-stage companies like Light Sciences will be beneficial to Micronics’ near and long term goals.”

“I’m very excited about Micronics’ prospects having previously served as a scientific advisor to the company in its formative years, and tracking the tremendous advances in near patient diagnostic testing made since that time,” said Luderer. “I believe that Micronics has one of the most important and proven product pipelines and technology platforms that offer rapid, affordable and highly accurate tests of value to patients, care givers and the medical system alike.”

Dr. Luderer has held a number of global and domestic management positions in the healthcare and diagnostics industry. Prior to joining Biotrove Inc. he served as president and chief executive officer at Light Sciences Corporation, a biotechnology start up developing novel therapies for oncology, cardiology and ophthalmologic disease. He previously served as president and chief operating officer for bioMerieux, Inc., a global provider of infectious disease in vitro diagnostic systems, where he restructured the US manufacturing and R & D operations to successfully launch VITEK 2, repositioned US-based immunoassay activities to molecular diagnostics, integrated newly acquired businesses, and established an exclusive genomic discovery partnership agreement. Dr. Luderer formerly served as vice president of technology development for Boehringer Mannheim Corporation where he directed all chemistry and discovery-related activities. During his tenure, Boehringer’s first electrochemical-based glucose monitor system ACCU-CHECK ADVANTAGE was successfully developed and launched. He received his doctorate in immunogenetics from Rutgers University where he was a National Science Foundation predoctoral fellow.

About Micronics Micronics is a privately held company based in Redmond, WA that is advancing a portfolio of point of care products for disease detection, diagnosis and treatment monitoring. The company employs an important patent estate in microfluidics and related technologies that make it possible to process biological samples directly in disposable devices and perform highly accurate, affordable tests in a fraction of the time. The company also provides custom development services for others that require access to Micronics’ intellectual property. For additional information, please visit